<DOC>
	<DOCNO>NCT00467831</DOCNO>
	<brief_summary>This study examine whether five drug ( pravastatin , Losartan , Zileuton , N-acetylcysteine erythromycin ) use together slow course pulmonary fibrosis ( scar lung tissue ) patient Hermansky-Pudlak Syndrome ( HPS ) . Patients disease decrease skin color ( albinism ) , bleed problem , sometimes colon problem . Two known type Hermansky Pudlak syndrome , type 1 type 4 , high risk pulmonary fibrosis age 30 50 . Patients 18 70 year age Hermansky-Pudlak Syndrome serious loss lung function due pulmonary fibrosis may eligible study . Participants begin take pravastatin study day 2 start new drug every 3 day . Patients experience problem medicine return home continue drug next 2 year . They return NIH Clinical Center every 3 month medical history , physical examination , blood , urine lung function test . CT bone density scan do every year . The study may continue 3 year .</brief_summary>
	<brief_title>Pilot Study Multi-Drug Regimen Severe Pulmonary Fibrosis Hermansky-Pudlak Syndrome</brief_title>
	<detailed_description>Hermansky-Pudlak Syndrome ( HPS ) rare autosomal recessive disease consist oculocutaneous albinism platelet storage pool defect . The serious complication disorder , pulmonary fibrosis , occur genetic subtypes HPS-1 HPS-4 generally fatal fourth fifth decade . HPS-1 common northwest Puerto Rico . There effective treatment pulmonary disease HPS ( HPS-PF ) , resemble idiopathic pulmonary fibrosis ( IPF ) . A preliminary study antifibrotic drug , pirfenidone , give promising result mild moderate HPS-PF , severe pulmonary fibrosis . A second study currently address mild moderate HPS-PF . Other drug , study IPF single agent , efficacy mild moderate disease , none major effect mortality . Recently , call make consideration multi-drug therapy ( i.e. , oncologic approach ) severe pulmonary fibrosis . Based upon positive response company produce relevant drug , propose multi-drug trial use five agent : Losartan , Zileuton , generic statin ( Pravastatin ) , generic N-acetylcysteine , generic Erythromycin . Participants severe pulmonary fibrosis drawn largely Puerto Rican population . Eligibility require molecular diagnosis HPS-1 HPS-4 , radiographic evidence interstitial lung disease , persistent pulmonary function test less equal 45 % predicted bronchodilation , absence cause lung dysfunction . Participants admit NIH Clinical Center 21-day admission establish baseline function begin medication therapy . Follow-up admission ( 3 day ) occur every 3 month . The primary outcome parameter survival 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Albinism</mesh_term>
	<mesh_term>Hermanski-Pudlak Syndrome</mesh_term>
	<mesh_term>Albinism , Oculocutaneous</mesh_term>
	<mesh_term>Platelet Storage Pool Deficiency</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Zileuton</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>INCLUSION CRITERIA : To eligible protocol , participant must : Have molecular diagnosis HPS1 HPS4 Be 1870 year age Have expectation live 3 month , i.e. , FVC great equal 30 % predict Have evidence severe pulmonary fibrosis , i.e . : 1 . A FVC less equal 45 % predict 2 . Reduced exercise tolerance lasting longer 1 week Dyspnea Perception Scale 3 . No evidence improvement pulmonary fibrosis within past year , define FVC increase 10 % DLco increase 15 % . Be available , willing , able come NIH Clinical Center admission every 3 month . EXCLUSION CRITERIA : An explanation interstitial lung disease HPS , include limited radiation , sarcoidosis , hypersensitivity pneumonitis , bronchiolitis obliterans organize pneumonia , cancer Pregnancy lactation History ethanol abuse recreational drug use past two year History human immunodeficiency virus ( HIV ) chronic viral hepatitis infection Chronic use highdose steroid ( great 10 mg prednisone/day ) intend ongoing treatment interstitial lung disease Use follow within 28 day enrollment : investigational therapy , cytotoxic/immunosuppressive agent corticosteroid , include limited azathioprine , cyclosphosphamide , methotrexate , cyclosporine , colchicine , interferon gamma1b , bosentan ; Any severe medical complication include limited uncontrolled seizure , repeat transient ischemic attack , severe ataxia , uncontrolled migraine headache , diplopia , repeat episode syncope , untreated psychiatric disorder , recent myocardial infarction ( past 6 month ) , unstable angina , clinically relevant untreated arrhythmia , uncontrolled hypotension hypertension ( systolic blood pressure le 80 great 180 mm Hg ) , myocarditis , severe congestive leave sided heart failure , hepatomegaly due right heart failure , renal glomerular impairment ( creatinine clearance le 35 ml/min/1.73 ( 2 ) ) , pancreatitis , toxic thyroiditis , lifethreatening malignancy ; NOTE : right side heart failure due pulmonary hypertension result pulmonary fibrosis consider exclusion criterion . Significant laboratory abnormality , include limited serum potassium le 3.0 great 5.4 mEq/L , SGPT great 100 U/L , CK great 700 U/L , hemoglobin le 9.0 g/dL , platelets less 70 k/mm ( 3 ) , leukocyte count le 2.0 k/microL ; For woman childbearing age , failure effective method birth control . Oral contraceptive consider inadequate without second method due risk reduce efficacy BCP take Zileuton . Severe psychiatric disease untreated . Inability give inform consent read consent read participant native language . Any concern therapeutic misconception evaluate genetic counselor and/or appropriate mental health professional prior acceptance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Restrictive Lung Disease</keyword>
	<keyword>Pulmonary Fibrosis</keyword>
	<keyword>Albinism</keyword>
	<keyword>Platelet Storage Pool Deficiency</keyword>
	<keyword>Metabolic Disease</keyword>
	<keyword>Hermansky-Pudlak Syndrome</keyword>
	<keyword>HPS</keyword>
	<keyword>Lung Disease</keyword>
</DOC>